Daiichi Sankyo soars on $22bn Merck cancer drugs deal

by

Shares in Japan’s Daiichi Sankyo soared on Friday after the pharma group announced a major cancer drug deal with US giant Merck worth up to $22 billion.

Leave A Comment

Your email address will not be published. Required fields are marked *